Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988608 | 1.00 | SPHK1 (0.50) | SPHK1DNM1USP2HTTLPAR1 | |
| SCHEMBL2994688 | 1.00 | SPHK1 (0.50) | SPHK1DNM1USP2HTTLPAR1 | |
| SCHEMBL2981074 | 1.00 | SPHK1 (0.50) | SPHK1DNM1USP2HTTLPAR1 | |
| SCHEMBL15346771 | 1.00 | SPHK1 (0.50) | SPHK1DNM1USP2HTTLPAR1 | |
| SCHEMBL1921025 | 0.86 | ALDH1A1 (0.56) | — | |
| SCHEMBL251629 | 0.82 | SPHK1 (0.43) | SPHK1DNM1USP2HTTLPAR1 | |
| SCHEMBL5561906 | 0.82 | SPHK1 (0.43) | SPHK1DNM1USP2HTTLPAR1 | |
| SCHEMBL11129695 | 0.81 | SPHK1 (0.47) | SPHK1DNM1USP2HTTTHRB | |
| SCHEMBL2995945 | 0.79 | MEN1 (0.39) | SPHK1DNM1USP2HTTLPAR1 | |
| SCHEMBL2998974 | 0.79 | MEN1 (0.39) | SPHK1DNM1USP2HTTLPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168450-A1 | NOVEL BRANCHED ALKOXYLATES | THOEN JOHAN A | 2010-07-01 | — | — | US | claimed |
| EP-2152652-A1 | NOVEL ALKYLOXY-ETHERS AND ALKOXYLATES THEREOF | Dow Global Technologies Inc. (US) | 2010-02-17 | — | — | EP | claimed |
| EP-2139833-A1 | NOVEL BRANCHED ALKOXYLATES | Dow Global Technologies Inc. (US) | 2010-01-06 | — | — | EP | claimed |
| WO-2008134390-A1 | NOVEL BRANCHED ALKOXYLATES | DOW GLOBAL TECHNOLOGIES INC. (US) | 2008-11-06 | — | — | WO | claimed |
| WO-2008134387-A1 | NOVEL ALKYLOXY-ETHERS AND ALKOXYLATES THEREOF | DOW GLOBAL TECHNOLOGIES INC. (US) | 2008-11-06 | — | — | WO | claimed |
| EP-2666459-A1 | PROCESS FOR PRODUCING VESICLE COMPOSITION | Kao Corporation (JP) | 2013-11-27 | — | — | EP | disclosed |
| US-20130287720-A1 | PROCESS FOR PREPARING VESICLE COMPOSITION | KAO CORPORATION (JP) | 2013-10-31 | — | — | US | disclosed |
| US-20100179354-A1 | NOVEL ALKOXY-ETHERS AND ALKOXYLATES THEREOF | THOEN JOHAN A | 2010-07-15 | — | — | US | disclosed |
| US-20100168450-A1 | NOVEL BRANCHED ALKOXYLATES | THOEN JOHAN A | 2010-07-01 | — | — | US | disclosed |
| EP-2152652-A1 | NOVEL ALKYLOXY-ETHERS AND ALKOXYLATES THEREOF | Dow Global Technologies Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| EP-2152653-A1 | NOVEL ALKOXYLATE-CONTAINING COMPOSITIONS | Dow Global Technologies Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| EP-2139833-A1 | NOVEL BRANCHED ALKOXYLATES | Dow Global Technologies Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008134390-A1 | NOVEL BRANCHED ALKOXYLATES | DOW GLOBAL TECHNOLOGIES INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008134387-A1 | NOVEL ALKYLOXY-ETHERS AND ALKOXYLATES THEREOF | DOW GLOBAL TECHNOLOGIES INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008134389-A1 | NOVEL ALKOXYLATE-CONTAINING COMPOSITIONS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| US-6392064-B2 | REACTING AN ALCOHOL WITH EPICHLOROHYDRIN WITH ALKALI METAL HYDROXIDE AND PHASE TRANSFER CATALYST | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2002-05-21 | — | — | US | disclosed |
| US-20020004605-A1 | Method of synthesizing glycidyl ether compounds in the absence of water and organic solvents | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130287720-A1 | PROCESS FOR PREPARING VESICLE COMPOSITION | CHMP4B, EXOSC9, EXOSC4 | SPHK1 1455/4885DNM1 1043/4885USP2 2843/4885 |
| US-20020004605-A1 | Method of synthesizing glycidyl ether compounds in the absence of water and organic solvents | TET2, DGAT1, ALKBH3 | SPHK1 1328/4885DNM1 568/4885USP2 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.